Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advancedovarian carcinoma: long-term results
Autore:
Bertucci, F; Viens, P; Delpero, JR; Bardou, VJ; Faucher, C; Houvenaeghel, G; Maraninchi, D;
Indirizzi:
Inst J Paoli I Calmettes, Dept Med Oncol, F-13273 Marseille 09, France Inst J Paoli I Calmettes Marseille France 09 -13273 Marseille 09, France Inst J Paoli I Calmettes, Dept Surg, F-13273 Marseille, France Inst J Paoli I Calmettes Marseille France F-13273 3273 Marseille, France Inst J Paoli I Calmettes, Dept Stat, F-13273 Marseille 09, France Inst J Paoli I Calmettes Marseille France 09 -13273 Marseille 09, France Inst J Paoli I Calmettes, Dept Hematol, F-13273 Marseille 09, France Inst J Paoli I Calmettes Marseille France 09 -13273 Marseille 09, France Univ Aix Marseille 2, F-13284 Marseille 07, France Univ Aix Marseille 2 Marseille France 07 2, F-13284 Marseille 07, France Univ Mediterranee, Marseille, France Univ Mediterranee Marseille FranceUniv Mediterranee, Marseille, France
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 1, volume: 26, anno: 2000,
pagine: 61 - 67
SICI:
0268-3369(200007)26:1<61:HMCAAS>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; 2ND-LOOK LAPAROTOMY; RESIDUAL DISEASE; CANCER PATIENTS; BREAST-CANCER; SOLID TUMORS; STAGE-III; RESCUE; SUPPORT; CYCLOPHOSPHAMIDE;
Keywords:
chemosensitive ovarian cancer; second look surgery; high-dose chemotherapy; melphalan; stem cells; long-term follow-up;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Bertucci, F Inst J Paoli I Calmettes, Dept Med Oncol, F-13273 Marseille 09, France Inst J Paoli I Calmettes Marseille France 09 ille 09, France
Citazione:
F. Bertucci et al., "High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advancedovarian carcinoma: long-term results", BONE MAR TR, 26(1), 2000, pp. 61-67

Abstract

The importance of dose intensity has been suggested in ovarian carcinoma, We retrospectively evaluated the long-term results of melphalan-based high-dose chemotherapy (HDC) with hematopoietic rescue in a unicentric series of33 patients with advanced ovarian cancer sensitive to first-line chemotherapy. Before HDC, treatment with debulking surgery and platinum-based chemotherapy was followed by second-look operation (SLO), HDC consisted of melphalan (n = 8), melphalan and cyclophosphamide (n = 9), or melphalan, etoposide and carboplatinum (n = 16), Toxicity was mainly hematological, One death occurred from infection during aplasia, With a median follow-up of 60 months after intensification, the 5-year progression-free survival (PFS) rate was 29% and the 5-year overall survival (OS) rate was 45%. Survival differed significantly according to tumor status at SLO, Women with microscopic or macroscopic disease at SLO, ie with a pathological partial response to first-line therapy (PPR), had survivals of 7% at 5 years, similar to other salvage therapies. Better results were obtained in the 20 n omen with a completepathological response (PCR) at SLO with 43% 5-year PFS (median, 51 months)and 75% 5-year OS (median not reached). In conclusion, melphalan-based HDCwith hematopoietic rescue had an acceptable toxicity in patients with chemosensitive advanced ovarian cancer. In situations of salvage therapy for patients in PPR, this treatment was not effective in long-term analysis. On the contrary, long-term results were favorable in patients with PCR, suggesting further prospective randomized studies comparing HDC and other consolidation treatments should be undertaken in this particular situation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 15:49:12